Table of Contents Author Guidelines Submit a Manuscript

An erratum for this article has been published. To view the erratum, please click here.

Canadian Journal of Gastroenterology
Volume 21, Suppl C, Pages 5C-24C
Canadian Consensus Guidelines

Management of Chronic Hepatitis B: Consensus Guidelines

Morris Sherman,1 Stephen Shafran,2 Kelly Burak,3 Karen Doucette,2 Winnie Wong,2 Nigel Girgrah,1 Eric Yoshida,4 Eberhard Renner,5 Philip Wong,6 and Marc Deschênes6

1Department of Medicine, University of Toronto, Toronto, Ontario, Canada
2Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
3Department of Medicine, University of Calgary, Calgary, Alberta, Canada
4Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
5Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
6Department of Medicine, McGill University, Montreal, Quebec, Canada

Copyright © 2007 Canadian Association for the Study of the Liver. This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (, which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.


The present document presents the proceedings of the consensus development conference on the management of viral hepatitis held in January 2007 under the auspices of the Canadian Association for the Study of the Liver and the Association of Medical Microbiology and Infectious Disease Canada. Several new agents have become available since the last such document was published in 2004, and new information has become available to help assess risk of adverse outcomes and who should be treated. In addition, the participants at the meeting identified a number of structural barriers that exist uniquely in Canada and that prevent physicians from properly managing their patients. The conference discussed the selection of patients for treatment and the drugs that can be used to treat these patients, as well as the treatment of hepatitis B in special populations. The present document should be read in conjunction with the companion document on the management of chronic hepatitis C.